Clinical Trials Directory

Trials / Completed

CompletedNCT04915729

A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity

A Phase III Multi-centre, Prospective, Randomised, Open Label, Blinded Endpoint (PROBE), Active-controlled Parallel Group Trial to Assess Efficacy and Safety of Tenecteplase Versus Alteplase in Chinese Patients With Acute Ischaemic Stroke Within 4.5 Hours After Stroke Onset

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
1,489 (actual)
Sponsor
Boehringer Ingelheim · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study is open to Chinese adults who had an ischaemic stroke, which means that blood vessels in the brain are blocked. To resolve blood clots, people in the study get either tenecteplase or alteplase within 4 hours and 30 minutes after stroke. The purpose of this study is to compare how tenecteplase and alteplase improve peoples' recovering of physical activity. Alteplase is standard of care. Tenecteplase is a modified variant of alteplase that is easier to administer and is approved to treat heart attack. This study is to find out whether tenecteplase is as good as alteplase in people with ischaemic stroke. Participants are equally put into 2 treatment groups by chance. Participants in one group get tenecteplase as a single injection into a vein. Participants in the other group get alteplase as an injection into a vein (10% of the dose) and the remainder as an infusion over 1 hour. Participants are in the study for about 3 months. They are in the hospital for the first week after treatment. Then they visit the study site 1 and 3 months after treatment. At these visits, peoples' ability to independently carry out daily activities is assessed. Scores for physical activity are compared between both treatment groups. The doctors also regularly check the general health of the participants.

Conditions

Interventions

TypeNameDescription
DRUGtenecteplasetenecteplase
DRUGalteplasealteplase

Timeline

Start date
2021-06-22
Primary completion
2023-10-08
Completion
2023-10-08
First posted
2021-06-07
Last updated
2024-12-10
Results posted
2024-12-10

Locations

55 sites across 1 country: China

Source: ClinicalTrials.gov record NCT04915729. Inclusion in this directory is not an endorsement.